View on market: Stay Cautious, be with quality business:

US equity futures and Asian equities fell early Monday after US inflation print piled the pressure on the Federal Reserve to intensify monetary tightening. Nasdaq 100 contracts lost over 1%, while those for the S&P 500 fell. Asian futures hinted at a decline. The Singapore-traded SGX Nifty — an early barometer of India’s benchmark Nifty 50 — fell more than 0.8% to 16,048 points as of 6:10 am. The dollar was firm on haven demand while oil retreated below $120 a barrel. Elsewhere, Bitcoin slipped below $27,000.

Economic Calendar:

  • INR: WPI Inflation on 13th June 2022.
  • INR: CPI Inflation on 13th June 2022.
  • USD: OPEC Monthly Report 14th June, 2022.
  • USD: US Interest Rate 15th June, 2022.

Brokerage Radar:

MORGAN STANLEY ON SUN PHARMA: OW, TP Rs 1032 Niche gPentasa – Quick Market Share Ramp Up Latest IQVIA weekly data shows a sharp increase in market share to 34.8%, within 3 weeks of launch Volumes were up 121% week-on-week, versus innovator’s down 31%, Assuming 40-50% discount/rebates & 40-50% volume share, estimate $50-70m sales upside for Sun (3-4% of Sun’s overall US sales) with high margins on a 12-month basis.

BANK OF AMERICA ON CAMPUS ACTIVEWEAR: Initiate Neutral, TP Rs 355 Long runaway for growth; strong innovation, execution Growth driven by industry tailwinds & self-help measures Competitiveness-vertically integrated & local supply chain Risks balanced: inflationary pressure bites.

CREDIT SUISSE ON MEDPLUS HEALTH: Initiate Neutral, TP  Rs 775, High growth phase but threat from e-pharmacies Initiate factoring in Co’s EBITDA margin expanding from 3.2% (4Q FY22) to 7-8% in steady state (prvt label mix increasing to 20%) & annual store addition of 1000 each for next 5 yrs.

CLSA ON RBL BANK: Downgrade to O-P from Buy, TP Rs 130 RBI approves R Subramaniakumar as MD & CEO Appointment raises several questions Leadership flux & liability headwinds, but asset quality manageable

@0.5x FY23/24CL PB STK is cheap, however, lacks material triggers.

UBS ON MARUTI: Buy, TP Rs 10000 SUV action starts 30th June 22 Set to launch next generation Brezza on 30th, followed by Toyota unveiling mid-size SUV Hyryder very next day Expect Maruti’s version of Toyota Hyryder to debut within weeks of Toyota unveil

International Markets:

U.S & Europe:

Particulars      10th June    Chg Chg(%)
Nasdaq 11,340.02 -414.21 -3.52
Dow 31392.79 -880.00 -2.73
FTSE 7,317.52 -158.69 -2.12
CAC 6,187.23 -171.23 -2.69
DAX 13,761.83 -436.97 -3.08
Dow Fut.* 31110.00     -284.8 -0.90

Asian markets:

Particulars    13th June    Chg. Chg(%)
SGX Nifty 15,875.50 -309.5 -1.91
Nikkei 27,088.86 -735.43 -2.64
Straits Times 3,155.41 -26.32 -0.83
Hang Seng 21,232.56 -573.62 -2.63
Shanghai 3,246.38 -38.45 -1.17

ADR Watch:

Particulars     10th June Chg. Chg.(%)
Dr Reddy 55.84 0.57 1.03
HDFC Bank 55.37 -2.63 -4.53
ICICI Bank 17.9 -0.55 -2.98
Infosys 18.33 -0.55 -2.91
Tata Motor 26.65 -0.5 -1.84
Wipro 5.7 -0.19 -3.23

Commodities & Currency:

Particulars Current Price Chg(%)
USD/INR 77.83 0.09
Brent 120.42  -1.34
Gold 1867.35 -0.45
Silver 21.672 -1.91


Particulars       10th June                                  9th June
FIIs -3973.95                        -1512.64                       
DIIs  2831.07  1624.90

News Update

Coal India: The company floated two international competitive bidding e-tenders of 3 million tons each, to source coal from abroad. The bids are for 5,000 GAR (gross as received) quality of thermal grade coal. These two medium term tenders for a total of 6 million tons coal quantity have an option of increasing the bid quantity by 100% to 12 MTs.

Vedanta: The company iron and steel sector has ventured into International Iron ore mining operations in Liberia, West Africa through its subsidiary Western Cluster.

IndInfravit: Brookfield Asset Management Inc. agreed to sell its entire equity shareholding in five road projects to IndInfravit Trust at an enterprise value of $1.2 billion (Rs 9,371.4 crore). The portfolio comprises three toll roads and two annuity roads with nearly 2,400 lane- kilometres in Andhra Pradesh, Bihar, Maharashtra, and Uttar Pradesh, it said.

GlaxoSmithKline Pharmaceuticals: Recommended dividend of Rs 90 per share including special dividend of Rs. 60, on face value of Rs 10 each.

Jammu & Kashmir Bank: Appointed Pratik D Punjabi as the Chief Financial Officer.

Future Supply Chain Solutions: The company has been facing challenges on account of frequent disruption of business operations at a few of its warehouses due to non‐payment/ part payments to the labour and on‐roll manpower who are intermittently disrupting the business activities at various warehouse locations.

Aban Offshore: To sell rig driller to ADNOC Drilling Co. for Rs 218 crore.

Bajaj Auto: Rolls out first electric scooter from plant in Pune; Chetak Tech, vendor partners to invest Rs 750 crore in EV plant.

Berger Paints: Says 1 contractual employee dies in Howrah fire.

Hindustan Zinc: DIPAM secretary says that government plans to sell residual stake in tranches.

IDBI Bank: Expression of interest for IDBI sale may come by July.

Laurus Labs: To spend up to 10% profit on disruptive technologies.

Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL